Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the revelation by federal prosecutors they may bring additional charges against former drug company CEO Martin Shkreli, which would be on top of the seven criminal counts he already is facing, including securities fraud; and a recommendation by an FDA panel that the risk plans for opioids need to be revised to cover immediate-release versions of those products, rather than just the extended-release and long-acting drugs, and require mandatory, instead of voluntary, prescriber training; plus other Washington news.

Advertisement

Related Content

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News
US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel